PMHNP Prescribing Authority and Evidence‑Based Practices for Medication‑Assisted Treatment (MAT)

Federal Prescribing Authority

Nurse practitioners, including PMHNPs, may obtain federal waivers to prescribe buprenorphine for opioid use disorder, with the specific scope of practice governed by state law. 1
Before the 2022 waiver elimination, PMHNPs were limited to treating 30 patients in the first year, expandable to 100 and up to 275 patients with additional qualifications. 1
PMHNPs can prescribe oral and extended‑release injectable naltrexone (Vivitrol) without any special federal waiver. 2
Methadone for opioid use disorder may be dispensed only through federally licensed opioid treatment programs, a restriction that applies to all prescribers regardless of professional designation. 4
In emergency situations, any DEA‑licensed provider may administer methadone for up to 72 hours while arranging referral to an OTP. 1

In 2016, California had only 7 physicians with buprenorphine waivers per 100,000 residents, underscoring the need to expand the prescriber pool to include PMHNPs. 6

First‑line MAT should consist of buprenorphine or methadone; extended‑release naltrexone is reserved for highly motivated patients who prefer an opioid‑free regimen or cannot access agonist therapy. 2
Buprenorphine treatment is associated with an ~80 % reduction in illicit opioid use and significant improvements in employment and other recovery outcomes. 5

All medication‑assisted treatments must be combined with evidence‑based behavioral therapies (e.g., cognitive‑behavioral therapy) to achieve optimal outcomes. 2
Team‑based care models that link PMHNPs with addiction specialists and other multidisciplinary providers improve clinician confidence and patient outcomes. 6
Combined pharmacotherapy + cognitive‑behavioral therapy yields greater efficacy than pharmacotherapy alone. 7

Screen patients for opioid use disorder using DSM‑5 criteria (≥ 2 criteria within the past 12 months). 2
Before initiating naltrexone, ensure the patient is completely opioid‑free (typically 7–10 days for short‑acting opioids, 10–14 days for long‑acting opioids) to avoid precipitated withdrawal. 3
Monitor liver function at baseline and every 3–6 months for patients receiving naltrexone because of potential hepatotoxicity. 3
Provide naloxone rescue kits to every patient receiving medication‑assisted treatment for opioid use disorder. 7

Some Medicaid programs impose formulary restrictions on buprenorphine due to cost, even though evidence shows buprenorphine has comparable mortality to methadone with lower average annual spending. 4
Advocacy for the removal of prior‑authorization requirements is essential to eliminate unnecessary delays in initiating MAT. 4

Utilize clinical support networks such as the Providers’ Clinical Support System (PCSS) and Project ECHO to enhance provider competence and facilitate collaborative MAT delivery. 6